Tumor necrosis factor

The Cytokine Handbook

Volumn , Issue , 2003, Pages 837-860

  Wang, Haichao ^a,b   Czura, Christopher J ^a   Tracey, Kevin J ^a  

^a North Shore LIJ Research Institute ^*  (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942923820     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012689663-3/50039-9     Document Type: Chapter

References (253)

1. Abraham E., Glauser M.P., Butler T., et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997, 277:1531-1538.
2. Abraham E., Anzueto A., Gutierrez G., et al. Doubleblind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock NORASEPT II Study Group. Lancet 1998, 351:929-933.
3. Abraham L.J., French M.A., Dawkins R.L. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-a. Clin. Exp. Immunol. 1993, 92:14-18.
4. Adam-Klages S., Adam D., Wiegmann K., et al. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell 1996, 86:937-947.
5. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996, 7:231-240.
6. Ahmed A.R., Yunis J.J., Marcus-Bagley D., et al. Major histocompatibility complex susceptibility genes for dermatitis herpetiformis compared with those for glutensensitive enteropathy. J. Exp. Med. 1993, 178:2067-2075.
7. Alessi D.R., Cuenda A., Cohen P., et al. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 1995, 270:27489-27494.
8. Alldred A. Etanercept in rheumatoid arthritis. Exp. Opin. Pharmacother. 2001, 2:1137-1148.
9. Alloatti G., Penna C., De Martino A., et al. Role of nitric oxide and platelet-activating factor in cardiac alterations induced by tumor necrosis factor-alpha in the guinea-pig papillary muscle. Cardiovasc. Res. 1999, 41:611-619.
10. An J., Ribeiro R.C., Webb P., et al. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc. Natl Acad. Sci. USA 1999, 96:15161-15166.
11. Apple R.J., Erlich H.A., Klitz W., et al. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat. Genet. 1994, 6:157-162.
12. Ashkenazi A., Marsters S.A., Capon D.J., et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc. Natl Acad. Sci. USA 1991, 88:10535-10539.
13. Auphan N., Di Donato J.A., Rosette C., et al. Immuno-suppression by glucocorticoids: inhibition of NFκB activity through induction of Iκ-B synthesis. Science 1995, 270:286-290.
14. Balboa M.A., Balsinde J., Aramburu J., et al. Phospholipase D activation in human natural killer cells through the KP43 and CD16 surface antigens takes place by different mechanisms. Involvement of the phospholipase D pathway in tumor necrosis factor-α synthesis. J. Exp. Med. 1992, 176:9-17.
15. Baldwin R.L., Stolowitz M.L., Hood L., et al. Structural changes of tumor necrosis factor α associated with membrane insertion and channel formation. Proc. Natl Acad. Sci. USA 1996, 93:1021-1026.
16. Barbara J.A., Smith W.B., Gamble J.R., et al. Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-α mutants. EMBO J. 1994, 13:843.
17. Beckham J.C., Caldwell D.S., Peterson B.L., et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J. Clin. Immunol. 1992, 12:353-361.
18. Benbadis S.R., Tatum W.O. Advances in the treatment of epilepsy. Am. Fam. Physician 2001, 64:91-98.
19. Bendtzen K., Morling N., Fomsgaard A., et al. Association between HLA-DR2 and production of tumour necrosis factor α and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand. J. Immunol. 1988, 28:599-606.
20. Bernik T.R., Ivanova S.M., Ochani M., et al. Vagus nerve stimulation attenuates cardiac TNF production in endotoxic shock. Shock 2001, 15(Supp.):27.
21. Bernik T.R., DiRaimo R., Friedman S.G., et al. Systemic anti-inflammatory action of CNI-1493 is mediated by the cholinergic anti-inflammatory pathway. J. Exp. Med. 2002, 18:781-788.
22. Bettinotti M.P., Hartung K., Deicher H., et al. Polymorphism of the tumor necrosis factor β gene in systemic lupus erythematosus: TNFB-MHC haplotypes. Immunogenetics 1993, 37:449-454.
23. Beutler B., Greenwald D., Hulmes J.D., et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985, 316:552-554.
24. Beutler B., Krochin N., Milsark I.W., et al. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986, 232:977-980.
25. Bevilacqua M.P., Pober J.S., Majeau G.R., et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc. Natl Acad. Sci. USA 1986, 83:4533-4537.
26. Bianchi M., Bloom O., Raabe T., et al. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J. Exp. Med. 1996, 183:927-936.
27. Biswas D.K., Ahlers C.M., Dezube B.J., et al. Pentoxifylline and other protein kinase C inhibitors down-regulate HIV-LTR NFκB-induced gene expression. Mol. Med. 1994, 1:31-43.
28. Black R.A., Rauch C.T., Kozlosky C.J., et al. A metal-loproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997, 385:729-733.
29. Blick M., Sherwin S.A., Rosenblum M., et al. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987, 47:2986-2989.
30. Bogdan C., Paik J., Vodovotz Y., et al. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β. J. Biol. Chem. 1992, 267:23301-23308.
31. Boise LH., Thompson C.B. Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc. Natl Acad. Sci. USA 1997, 94:3759-3764.
32. Boldin M.P., Goncharov T.M., Goltsev Y.V., et al. Involvement of mach, a novel MORT1/FADD-interacting protease, in Fas/Apo-1- and TNF receptor-induced cell death. Cell 1996, 85:803-815.
33. Borovikova L.V., Ivanova S., Nardi D., et al. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton. Neurosci. 2000, 85:141-147.
34. Borovikova L.V., Ivanova S., Zhang M., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405:458-462.
35. Bradley J.R., Johnson D.R., Pober J.S. Four different classes of inhibitors of receptor-mediated endocytosis decrease tumor necrosis factor-induced gene expression in human endothelial cells. J. Immunol. 1993, 150:5544-5555.
36. Brett J., Gerlach H., Nawroth P., et al. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J. Exp. Med. 1989, 169:1977-1991.
37. Brockhaus M., Schoenfeld H.J., Schlaeger E.J., et al. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl Acad. Sci. USA 1990, 87:3127-3131.
38. Bruce A.J., Boling W., Kindy M.S., et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 1996, 2:788-794.
39. Buck C., Digel W., Schoniger W., et al. Tumor necrosis factor-α, but not lymphotoxin, stimulates growth of tumor cells in hairy cell leukemia. Leukemia 1990, 4:431-434.
40. Cabrera M., Shaw M.A., Sharpies C., et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J. Exp. Med. 1995, 182:1259-1264.
41. Calandra T., Baumgartner J.D., Grau G.E., et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α and interferon-γ in the serum of patients with septic shock. Swiss-Dutch J5 immunoglobulin study group. J. Infect. Dis. 1990, 161:982-987.
42. Campbell D.A., Field M., McArdle C.S., et al. Polymorphism at the tumour necrosis factor locus: a marker of genetic predisposition to colorectal cancer?. Lancet 1994, 343:293-294. (letter).
43. Caput D., Beutler B., Hartog K., et al. Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl Acad. Sci. USA 1986, 83:1670-1674.
44. Carswell E.A., Old L.J., Kassel R.L., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 1975, 72:3666-3670.
45. Cha S.S., Kim J.S., Cho H.S., et al. High resolution crystal structure of a human tumor necrosis factor-α mutant with low systemic toxicity. J. Biol. Chem. 1998, 273:2153-2160.
46. Chainy G.B., Singh S., Raju U., et al. Differential activation of the nuclear factorκB by TNF muteins specific for the p60 and p80 TNF receptors. J. Immunol. 1996, 157:2410-2417.
47. Cheng B., Christakos S., Mattson M.P. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 1994, 12:139-153.
48. Cheng G., Baltimore D. Tank, a co-inducer with TRAF2 of TNF- and CD 401-mediated NFκB activation. Genes Dev. 1996, 10:963-973.
49. Chikanza I.C., Roux-Lombard P., Dayer J.M., et al. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin. Exp. Immunol. 1993, 92:19-22.
50. Chinnaiyan A.M., O'Rourke K., Tewari M., et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81:505-512.
51. Chu C.Q., Field M., Feldman M., et al. Localization of tumor necrosis factor-a in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991, 34:1125-1132.
52. Coeshott C., Ohnemus C., Pilyavskaya A., et al. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc. Natl Acad. Sci. USA 1999, 96:6261-6266.
53. Cohen O., Inbal B., Kissil J.L., et al. DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J. Cell Biol. 1999, 146:141-148.
54. Cohen P.S., Nakshatri H., Dennis J., et al. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc. Natl Acad. Sci. USA 1996, 93:3967-3971.
55. Condorelli G., Vigliotta G., Cafieri A., et al. PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene 1999, 18:4409-4415.
56. Cox A., Gonzalez A.M., Wilson A.G., et al. Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor α with human IDDM. Diabetologia 1994, 37:500-503.
57. Crawford E.K., Ensor J.E., Kalvakolanu I., et al. The role of 3' poly(A) tail metabolism in tumor necrosis factor-alpha regulation. J. Biol. Chem. 1997, 272:21120-21127.
58. Creasey AA., Doyle L.V., Reynolds M.T., et al. Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res. 1987, 47:145-149.
59. Cronin L., Cook D.J., Carlet J., et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care Med. 1995, 23:1430-1439.
60. Crowe P.D., Walter B.X., Mohler K.M., et al. A metal-loprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J. Exp. Med. 1995, 181:1205-1210.
61. Cuenda A., Rouse J., Doza Y.N., et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995, 364:229-233.
62. D'Alfonso S., Richiardi P.M. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994, 39:150-154.
63. D'Alfonso S., Colombo G., Della Bella S., et al. Association between polymorphisms in the TNF region and systemic lupus erythematosus in the Italian population. Tissue Antigens 1996, 47:551-555.
64. Dean J.L., Wait R., Mahtani K.R., et al. The 3' untranslated region of tumor necrosis factor alpha mRNA is a target of the mRNA-stabilizing factor HuR. Mol. Cell Biol. 2001, 21:721-730.
65. Dekkers P.E., Lauw F.N., ten Hove T., et al. The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia. Blood 1999, 94:2252-2258.
66. Denham W., Yang J., Wang H., et al. Inhibition of p38 mitogen activated kinase attenuates the severity of pancreatitis-induced adult respiratory distress syndrome. Crit. Care Med. 2000, 28:2567-2572.
67. Dhainaut J.F., Vincent J.L., Richard C., et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit. Care Med. 1995, 23:1461-1469.
68. Di Marco S., Hel Z., Lachance C., et al. Polymorphism in the 3'-untranslated region of TNFalpha mRNA impairs binding of the post-transcriptional regulatory protein HuR to TNFalpha mRNA. Nucleic Acids Res. 2001, 29:863-871.
69. Duan H., Dixit V.M. RAIDD is a new 'death' adaptor molecule. Nature 1997, 385:86-89.
70. Duerksen-Hughes P.J., Day D.B., Laster S.M., et al. Both tumor necrosis factor and nitric oxide participate in lysis of simian virus 40-transformed cells by activated macrophages. J. Immunol. 1992, 149:2114-2122.
71. Estrada C., Gomez C., Martin C., et al. Nitric oxide mediates tumor necrosis factor-α cytotoxicity in endothelial cells. Biochem. Biophys. Res. Commun. 1992, 186:475-482.
72. Fabris M., Di P.E., D'Elia A., et al. Tumor necrosis factor-alpha gene polymorphism in severe and mildmoderate rheumatoid arthritis. J. Rheumatol. 2002, 29:29-33.
73. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 2001, 19:163-196.
74. Feng G.J., Goodridge H.S., Harnett M.M., et al. Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J. Immunol. 1999, 163:6403-6412.
75. Fillit H., Ding W.H., Buee L., et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 1991, 129:318-320.
76. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389.
77. Fong C.W., Siddiqui A.H., Mark D.F. Characterization of protein complexes formed on the repressor elements of the human tumor necrosis factor alpha gene. J. Interferon Cytokine Res. 1995, 15:887-895.
78. Fong Y., Tracey K.J., Moldawer L.L., et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 1989, 170:1627-1633.
79. Gadient R.A., Cron K.C., Otten U. Interleukin-1β and tumor necrosis factor-α synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes. Neurosci. Lett. 1990, 117:335-340.
80. Gatanaga T., Hwang C.D., Gatanaga M., et al. The regulation of TNF receptor mRNA synthesis, membrane expression, and release by PMA- and LPS-stimulated human monocytic THP-1 cells in vitro. Cell Immunol. 1991, 138:1-10.
81. Gearing A.J., Beckett P., Christodoulou M., et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994, 370:555-557.
82. Gearing A.J., Beckett P., Christodoulou M., et al. Matrix metalloproteinases and processing of pro-TNF-α. J. Leukoc. Biol. 1995, 57:774-777.
83. Girardin E., Grau G.E., Dayer J.M., et al. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N. Engl. J. Med. 1988, 319:397-400.
84. Girardin E., Roux-Lombard P., Grau G.E., et al. Imbalance between tumour necrosis factor-α and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology 1992, 76:20-23.
85. Giroir B.P., Horton J.W., White D.J., et al. Inhibition of tumor necrosis factor prevents myocardial dysfunction during burn shock. Am. J. Physiol. 1994, 267:H118-H124.
86. Goldfeld A.E., McCaffrey P.G., Strominger J.L., et al. Identification of a novel cyclopsporin-sensitive element in the human tumor necrosis factor α gene promoter. J. Exp. Med. 1993, 178:1365-1379.
87. Goodnick P.J., Rush A.J., George M.S., et al. Vagus nerve stimulation in depression. Expert Opin. Pharmacother. 2001, 2:1061-1063.
88. Grell M., Douni E., Wajant H., et al. The transmenbrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83:793-802.
89. Grimaldi L.M., Martino G.V., Franciotta D.M., et al. Elevated α-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. Ann. Neurol. 1991, 29:21-25.
90. Grimm S., Stanger B.Z., Leder P. RIP and FADD: two 'death domain'-containing proteins can induce apoptosis by convergent, but dissociable, pathways. Proc. Natl Acad. Sci. USA 1996, 93:10923-10927.
91. Gueydan C., Droogmans L., Chalon P., et al. Identification of TIAR as a protein binding to the translational regulatory AU-rich element of tumor necrosis factor alpha mRNA. J. Biol. Chem. 1999, 274:2322-2326.
92. Guha M., O'Connell M.A., Pawlinski R., et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001, 98:1429-1439.
93. Habib F.M., Springall D.R., Davies G.J., et al. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet. 1996, 347:1151-1155.
94. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 1990, 172:391-394.
95. Hegewisch S., Weh H.J., Hossfeld D.K. TNF-induced cardiomyopathy. Lancet 1990, 335:294-295. (letter).
96. Hill A.V. Malaria resistance genes: a natural selection. Trans. R. Soc. Trop. Med. Hyg. 1992, 86:225-226.
97. Hill A.V. Malaria resistance genes: a natural selection. Trans. R. Soc. Trop. Med. Hyg. 1992, 86:232.
98. Hofman P.M., Hinton D.R., Johnson K., et al. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 1989, 170:607-612.
99. Hohmann H.P., Remy R., Brockhaus M., et al. Two different cell types have different major receptors for human tumor necrosis factor (TNF-α). J. Biol. Chem. 1989, 264:14927-14934.
100. Hohmann H.P., Brockhaus M., Baeuerle P.A., et al. Expression of the types A and B tumor necrosis factor (TNF) receptors is independently regulated, and both receptors mediate activation of the transcription factor NFκB. TNF-α is not needed for induction of a biological effect via TNF receptors. J. Biol. Chem. 1990, 265:22409-22417.
101. Hsu H., Xiong J., Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NFκB activation. Cell 1995, 81:495-504.
102. Hsu H., Shu H.B., Pan M.G., et al. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996, 84:299-308.
103. Jacob C.O., Fronek Z., Lewis G.D., et al. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor α: relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 1990, 87:1233-1237.
104. Jones E.Y., Stuart D.I., Walker N.P. Structure of tumour necrosis factor. Nature 1989, 338:225-228.
105. Jongeneel C.V., Briant L., Udalova I.A., et al. Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes. Proc. Natl Acad. Sci. USA 1991, 88:9717-9721.
106. Kam L.Y., Targan S.R. TNF-alpha antagonist for the treatment of Crohn's disease. Expert Opin. Pharmacother. 2000, 1:615-622.
107. Kapadia S., Torre-Amione G., Yokoyama T., et al. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-α in vitro. Am. J. Physiol. 1995, 268:H517-H525.
108. Katz S.D., Rao R., Berman J.W., et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994, 90:12-16.
109. Kohno T., Brewer M.T., Baker S.L., et al. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc. Natl Acad. Sci. USA 1990, 87:8331-8335.
110. Kouba D.J., Nakano H., Nishiyama T., et al. Tumor necrosis factor-α induces distinctive NFκB signaling within human dermal fibroblasts. J. Biol. Chem. 2001, 276:6214-6224.
111. Kramer B., Meichle A., Hensel G., et al. Characterization of a KROX-24/EGR-1-responsive element in the human tumor necrosis factor promoter. Biochim. Biophys. Acta 1994, 1219:413-421.
112. Kramer B., Wiegmann K., Kronke M. Regulation of the human TNF promoter by the transcription factor Ets. J. Biol. Chem. 1995, 270:6577-6583.
113. Kriegler M., Perez C., De Fay K., et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988, 53:45-53.
114. Kruys V., Marinx O., Shaw G., et al. Translational blockade imposed by cytokine-derived UA-rich sequences. Science 1989, 245:852-855.
115. Kwiatkowski D., Hill A.V., Sambou I., et al. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990, 336:1201-1204.
116. Lacraz S., Nicod L., Galve-de Rocnemonteix B., et al. Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J. Clin. Invest. 1992, 90:382-388.
117. Lacraz S., Nicod L.P., Chicheportiche R., et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest. 1995, 96:2304-2310.
118. Lai W.S., Carballo E., Strum J.R., et al. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol. Cell. Biol. 1999, 19:4311-4323.
119. Lee E., Vaughan D.E., Parikh S.H., et al. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ. Res. 1996, 78:44-49.
120. Lee F.S., Hagler J., Chen Z.J., et al. Activation of the IκBα kinase complex by MEKK1, a kinase of the JNK pathway. Cell 1997, 88:213-222.
121. Lee J.C., Laydon J.T., McDonnell P.C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372:739-746.
122. Leeuwenberg J.F., Jeunhomme T.M., Buurman W.A. Slow release of soluble TNF receptors by monocytes in vitro. J. Immunol. 1994, 152:4036-4043.
123. Leist T.P., Frei I.C., Kam-Hansen S., et al. Tumor necrosis factor-α in cerebrospinal fluid during bacterial, but not viral, meninigitis. Evaluation in murine model infections and in patients. J. Exp. Med. 1988, 167:1743-1748.
124. Leitman D.C., Mackow E.R., Williams T., et al. The core promoter region of the tumor necrosis factor α gene confers phorbol ester responsiveness to upstream transcriptional activators. Mol. Cell Biol. 1992, 12:1352-1356.
125. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 1990, 323:236-241.
126. Lienard D., Ewalenko P., Delmotte J.J., et al. High-dose recombinant tumor necrosis factor α in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 1992, 10:52-60.
127. Lilly C.M., Sandhu J.S., Ishizaka A., et al. Pentoxifylline prevents tumor necrosis factor-induced lung injury. Am. Rev. Respir. Dis. 1989, 139:1361-1368.
128. Lin L.L., Wartmann M., Lin A.Y., et al. CPLA2 is phosphorylated and activated by MAP kinase. Cell 1993, 72:269-278.
129. Lin L.S. Tumor Necrosis Factor: The Molecules and Their Emerging Role in Medicine 1992, 33-48. Raven Press, New York. B. Beutler (Ed.).
130. Lin R.H., Hwang Y.W., Yang B.C., et al. TNF receptor-2-triggered apoptosis is associated with the down-regulation of Bcl-xL on activated T cells and can be prevented by CD28 costimulation. J. Immunol. 1997, 158:598-603.
131. Liu T., Clark R.K., McDonnell P.C., et al. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 1994, 25:1481-1488.
132. Liu Z.G., Hsu H., Goeddel D.V., et al. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NFκB activation prevents cell death. Cell 1996, 87:565-576.
133. Loetscher H., Stueber O., Banner D., et al. Human tumor necrosis factor α (TNF α) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J. Biol. Chem. 1993, 268:26350-26357.
134. Lovell D.J., Giannini E.H., Reiff A., et al. Etanercept in children with plyarticular juvenile rheumatoid arthritis. N. Engl J. Med. 2000, 342:763-769.
135. Machleidt T., Kramer B., Adam D., et al. Function of the p55 tumor necrosis factor receptor 'death domain' mediated by phosphatidylcholine-specific phospholipase C. J. Exp. Med. 1996, 184:725-733.
136. Mackay F., Rothe J., Bluethmann H., et al. Differential responses of fibroblasts from wild-type and TNF-r55-deficient mice to mouse and human TNF-α activation. J. Immunol. 1994, 153:5274-5284.
137. Maini R., St.Clair E.W., Breeveld F., et al. Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999, 354:1932-1939.
138. Majetschak M., Flohe S., Obertacke U., et al. Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann. Surg. 1999, 230:207-214.
139. Malinin N.L., Boldin M.P., Kovalenko A.V., et al. MAP3K-related kinase involved in NFκB induction by TNF, CD95 and IL-1. Nature 1997, 385:540-544.
140. Mallett S., Barclay A.N. A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol. Today 1991, 12:220-223.
141. Mandrup-Poulsen T., Bendtzen K., Dinarello C.A., et al. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic β-cell cytotoxicity. J. Immunol. 1987, 139:4077-4082.
142. Manus R.M., Wilson A.G., Mansfield J., et al. TNF2, a polymorphism of the tumour necrosis-α gene promoter, is a component of the celiac disease major histocompatibility complex haplotype. Eur. J. Immunol. 1996, 26:2113-2118.
143. Markman M., Braine H.G., Abeloff M.D. Histocompatibility antigens in small cell carcinoma of the lung. Cancer 1984, 54:2943-2945.
144. Marx J. How the glucocorticoids suppress immunity. Science 1995, 270:232-233.
145. Mattson M.P., Zhang Y., Bose S. Growth factors prevent mitochondrial dysfunction, loss of calcium homeostasis, and cell injury, but not ATP depletion in hippocampal neurons deprived of glucose. Exp. Neurol. 1993, 121:1-13.
146. McGeehan G.M., Becherer J.D., Bast R.C., et al. Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994, 370:558-561.
147. McGuire W., Hill A.V., Allsopp C.E., et al. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994, 371:508-510.
148. McManus R., Moloney M., Borton M., et al. Association of celiac disease with microsatellite polymorphisms close to the tumor necrosis factor genes. Hum. Immunol. 1996, 45:24-31.
149. McNamara M.J., Norton J.A., Nauta R.J., et al. Interleukin-1 receptor antibody (IL-1RAB) protection and treatment against lethal endotoxemia in mice. J. Surg. Res. 1993, 54:316-321.
150. Mehler M.F., Rozental R., Dougherty M., et al. Cytokine regulation of neuronal differentiation of hippocampal progenitor cells. Nature 1993, 362:62-65.
151. Meistrell M., Botchkina G.I., Wang H., et al. TNF is a brain-damaging cytokine in cerebral ischemia. Shock 1997, 8:341-348.
152. Meyer C.G., Gallin M., Erttmann K.D., et al. HLA-D alleles associated with generalized disease, localized disease, and putative immunity in Onchocerca volvulus infection. Proc. Natl Acad. Sci. USA 1994, 91:7515-7519.
153. Millar A.B., Foley N.M., Singer M., et al. Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet 1989, ii:712-714.
154. Mohler K.M., Torrance D.S., Smith C.A., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 1993, 151:1548-1561.
155. Molvig J., Baek L., Christensen P., et al. Endotoxin-stimulated human monocyte secretion of interleukin 1, tumour necrosis factor α, and prostaglandin E2 shows stable interindividual differences. Scand. J. Immunol. 1988, 27:705-716.
156. Moriarty T.M., Padrell E., Carty D.J., et al. GO protein as signal transducer in the pertussis toxin-sensitive phosphatidylinositol pathway. Nature 1990, 343:79-82.
157. Moser R.B., Schleiffenbaum B., Groscurth P., et al. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J. Clin. Invest. 1989, 83:444-455.
158. Moss M.L., Jin S.L., Milla M.E., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997, 385:733-736.
159. Mullberg J., Durie F.H., Otten-Evans C., et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J. Immunol. 1995, 155:5198-5205.
160. Müller G., Ayoub M., Storz P., et al. PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. EMBO J. 1995, 14:1961-1969.
161. Muzio M., Chinnaiyan A.M., Kischkel F.C., et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85:817-827.
162. Narhi L.O., Philo J.S., Li T., et al. Induction of α-helix in the β-sheet protein tumor necrosis factor-α: acid-induced denaturation. Biochemistry 1996, 35:11454-11460.
163. Natanson C., Eichenholz P.W., Danner R.L., et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human spetic shock. J. Exp. Med. 1989, 169:823-832.
164. Natoli G., Costanzo A., Ianni A., et al. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 1997, 275:200-203.
165. Nawroth P.P., Bank I., Handley D., et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J. Exp. Med. 1986, 163:1363-1375.
166. North R.J., Havell E.A. The antitumor function of tumor necrosis factor (TNF). II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J. Exp. Med. 1988, 167:1086-1099.
167. Ohkawa S., Wright K.C., Mahajan H., et al. Hepatic arterial infusion of human recombinant tumor necrosis factor-α. An experimental study in dogs. Cancer 1989, 63:2096-2102.
168. Panagakos F.S., O'Boskey J.F., Rodriguez E. Regulation of pulp cell matrix metalloproteinase production by cytokines and lipopolysaccharides. J. Endod. 1996, 22:358-361.
169. Partanen J., Koskimies S. Low degree of DNA polymorphism in the HIA-linked lymphotoxin (tumour necrosis factor β) gene. Scand. J. Immunol. 1988, 28:313-316.
170. Pena L.A., Fuks Z., Kolesnick R. Stress-induced apoptosis and the sphingomyelin pathway. Biochem. Pharmacol. 1997, 53:615-621.
171. Peppel K., Crawford D., Beutler B. A tumor necrosis factor (TNF) receptor-IGG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 1991, 174:1483-1489.
172. Pfeffer K., Matsuyama T., Kundig T.M., et al. Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993, 73:457-467.
173. Piecyk M., Wax S., Beck A.R., et al. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J. 2000, 19:4154-4163.
174. Pincus T., Brooks R.H., Callahan L.F. Prediction of long-term mortality inpatients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann. Intern. Med. 1994, 120:26-34.
175. Plata-Salaman C.R. Immunoregulators in the nervous system. Neurosci. Biobehav. Rev. 1991, 15:185-215.
176. Pociot F., Briant L., Jongeneel C.V., et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α and TNF-β by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur. J. Immunol. 1993, 23:224-231.
177. Pociot F., Wilson A.G., Nerup J., et al. No independent association between a tumor necrosis factor-α promoter region polymorphism and insulin-dependent diabetes mellitus. Eur. J. Immunol. 1993, 23:3050-3053.
178. Rood M.J., van Krugten M.V., Zanelli E., et al. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 2000, 43:129-134.
179. Rothe M., Sarma V., Dixit V.M., et al. TRAF2-mediated activation of NFκB by TNF receptor 2 and CD40. Science 1995, 269:1424-1427.
180. Sampaio E.P., Sarno E.N., Galilly R., et al. Thalido-mide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J. Exp. Med. 1991, 173:699-703.
181. Sandborn W.J., Hanauer S.B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 1999, 5:119-133.
182. Sato N., Goto T., Haranaka K., et al. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J. Natl Cancer Inst. 1986, 76:1113-1121.
183. Sato Y., Koshita Y., Hirayama M., et al. Augmented antitumor effects of killer cells induced by tumor necrosis factor gene-transduced autologous tumor cells from gastrointestinal cancer patients. Hum Gene Ther. 1996, 7:1895-1905.
184. Saukkonen K., Sande S., Cioffe C., et al. The role of cytokines in the generation of inflammation and tissue damage in experimental Gram-positive meningitis. J. Exp. Med. 1990, 171:439-448.
185. Scheinman R.I., Cogswell P.C., Lofquist A.K., et al. Role of transcriptional activation of IκB α in mediation of immunosuppression by glucocorticoids. Science 1995, 270:283-286.
186. Schiller J.H., Win P.L., Storer B., et al. Clinical and biologic effects of combination therapy with γ-interferon and tumor necrosis factor. Cancer 1992, 69:562-571.
187. Schutze S., Potthoff K., Machleidt T., et al. TNF activates NFκB by phosphatidylcholine-specific phospholipase C-induced 'acidic' sphingomyelin breakdown. Cell 1992, 71:765-776.
188. Schwarz E.M., Looney R.J., O'Keefe R.J. Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res. 2000, 2:165-168.
189. Seckinger P., Isaaz S., Dayer J.M. Purification and biologic characterization of a specific tumor necrosis factor α inhibitor. J. Biol. Chem. 1989, 264:11966-11973.
190. Segal R., Dayan M., Zinger H., et al. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFα monoclonal antibody and by pentoxiphylline. Lupus 2001, 10:23-31.
191. Ségui B., Bezombes C., Uro-Coste E., et al. Stress-induced apoptosis is not mediated by endolysosomal ceramide. FASEB J. 2000, 14:36-47.
192. Selmaj K.W., Farooq M., Norton W.T., et al. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J. Immunol. 1990, 144:129-135.
193. Shanahan F. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for). Inflamm. Bowel Dis. 2000, 6:137-139.
194. Shaw G., Kamen R. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986, 46:659-667.
195. Shimura T., Hagihara M., Takebe K., et al. The study of tumor necrosis factor β gene polymorphism in lung cancer patients. Cancer 1994, 73:1184-1188.
196. Shingu M., Nagai Y., Isayama T., et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin. Exp. Immunol. 1993, 94:145-149.
197. Singh I.S., He J.R., Calderwood S., et al. A high affinity HSF-1 binding site in the 5'-untranslated region of the murine tumor necrosis factor-(alpha) gene is a transcriptional repressor. J. Biol. Chem. 2001, 15:4981-4988.
198. Silver I.A., Murrills R.J., Etherington D.J. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp. Cell Res. 1988, 175:266-276.
199. Smith R.A., Baglioni C. The active form of tumor necrosis factor is a trimer. J. Biol. Chem. 1987, 262:6951-6954.
200. Smith R.A., Baglioni C. Characterization of TNF receptors. Immunol. Ser. 1992, 56:131-147.
201. Sollid L.M., Markussen G., Ek J., et al. Evidence for a primary association of celiac disease to a particular HLA-DQα/β heterodimer. J. Exp. Med. 1989, 169:345-350.
202. Spence M.W. Sphingomyelinases. Adv. Lipid Res. 1993, 26:3-23.
203. Stanger B.Z., Leder P., Lee T.H., et al. RIP: a novel protein containing a death domain that interacts with FAS/APO-1 (CD95) in yeast and causes cell death. Cell 1995, 81:513-523.
204. Stephens K.E., Ishizaka A., Wu Z.H., et al. Granulocyte depletion prevents tumor necrosis factor-mediated acute lung injury in guinea pigs. Am. Rev. Respir. Dis. 1988, 138:1300-1307.
205. Stuber F., Petersen M., Bokelmann F., et al. A genomic polymorphims within the tumor necrosis factor locus influences plasma tumor necrosis factor-a concentrations and outcome of patients with severe sepsis. Crit. Care Med. 1996, 24:381-384.
206. Suffredini A.F., Fromm R.E., Parker M.M., et al. The cardiovascular response of normal humans to the administration of endotoxin. N. Engl J. Med. 1989, 321:280-287.
207. Sugarman B.J., Aggarwal B.B., Hass P.E., et al. Recombinat human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science 1985, 230:943-945.
208. Tartaglia L.A., Weber R.F., Figari I.S., et al. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl Acad. Sci. USA 1991, 88:9292-9296.
209. Tartaglia L.A., Ayres T.M., Wong G.H., et al. A novel domain within the 55 kD TNF receptor signals cell death. Cell 1993, 74:845-853.
210. Tartaglia L.A., Pennica D., Goeddel D.V. Ligand passing: the 75-kDA tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J. Biol. Chem. 1993, 268:18542-18548.
211. Taylor P.C. Anti-tumor necrosis factor therapies. Curr. Opin. Rheumatol. 2001, 13:164-169.
212. Thomson A.M. Neuroscience. More than just frequency detectors?. Science 1997, 275:179-180.
213. Tracey K.J. Suppression of TNF and other proinflammatory cytokines by the tetravalent guanylhydrazone CNI-1493. Prog. Clin. Biol. Res. 1998, 397:335-343.
214. Tracey K.J., Cerami A. Metabolic responses to cachectin/TNF. A brief review. Ann. NY Acad. Sci. 1990, 587:325-331.
215. Tracey K.J., Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 1994, 45:491-503.
216. Tracey K.J., Beutler B., Lowry S.F., et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986, 234:470-474.
217. Tracey K.J., Lowry S.F., Beutler B., et al. Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J. Exp. Med. 1986, 164:1368-1373.
218. Tracey K.J., Fong Y., Hesse D.G., et al. Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987, 330:662-664.
219. Tracey K.J., Lowry S.F., Fahey T.J., et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg. Gynecol. Obstet. 1987, 164:415-422.
220. Tracey K.J., Wei H., Manogue K.R., et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J. Exp. Med. 1988, 167:1211-1227.
221. Tracey K.J., Vlassara H., Cerami A. Cachectin/tumour necrosis factor. Lancet 1989, i:1122-1126.
222. Tsai E.Y., Yie J., Thanos D., et al. Cell-type-specific regulation of the human tumor necrosis factor-α gene in B cells and T cells by NFATP and ATF-2/Jun. Mol. Cell Biol. 1996, 16:5232-5244.
223. Tsuchiya N., Kawasaki A., Tsao B.P., et al. Analysis of the association of HLA-DRB1, TNFalpha promoter and TNFR2 (TNFRSF1B) polymorphisms with SLE using transmission disequilibrium test. Genes Immun. 2001, 2:317-322.
224. Tsutsumi Y., Kihira T., Tsunoda S., et al. Molecular design of hybrid tumour necrosis factor-α with polyethylene glycol increases its anti-tumour potency. Br. J. Cancer 1995, 71:963-968.
225. Udalova I.A., Nedospasov S.A., Webb G.C., et al. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 1993, 16:180-186.
226. Van Antwerp D.J., Martin S.J., Kafri T., et al. Suppression of TNF-α-induced apoptosis by NFκB. Science 1996, 274:787-789.
227. van der Goot F.G., Pugin J., Hribar M., et al. Membrane interaction of TNF is not sufficient to trigger increase in membrane conductance in mammalian cells. FEBS Lett. 1999, 460:107-111.
228. van der Linden M.W., van der Slik A.R., Zanelli E., et al. Six microsatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNF-308A in systemic lupus erythematosus. Genes Immun. 2001, 2:373-380.
229. van der Poll T., Lowry S.F. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense?. Shock 1995, 3:1-12. (editorial).
230. Van Ostade X., Vandenabeele P., Everaerdt B., et al. Human TNF mutants with selective activity on the p55 receptor. Nature 1993, 361:266-269.
231. Van Zee K.J., Stackpole S.A., Montegut W.J., et al. A human tumor necrosis factor (TNF) a mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J. Exp. Med. 1994, 179:1185-1191.
232. Via C.S., Shustov A., Rus V., et al. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J. Immunol. 2001, 167:6821-6826.
233. Waage A., Brandtzaeg P., Halstensen A., et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1. and fatal outcome. J. Exp. Med. 1989, 169:333-338.
234. Wang C.Y., Mayo M.W., Baldwin A.S. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NFκB. Science 1996, 274:784-787.
235. Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a recombinant tumor necrosis factor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl J. Med. 1999, 340:253-259.
236. Welch T.R., Beischel L.S., Balakrishnan K., et al. Major histocompatibility complex extended haplotypes in systemic lupus erythematosus. Dis. Markers 1988, 6:247-255.
237. Weegmann K., Schutze S., Machleidt T., et al. Functional dichotomy of neutral and acidic sphin-gomyelinases in tumor necrosis factor signaling. Cell 1994, 78:1005-1015.
238. Wilson A.G., de Vries N., Pociot F., et al. An allelic polymorphism within the human tumor necrosis factor-α promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J. Exp. Med. 1993, 177:557-560.
239. Wilson A.G., Gordon C., Di Giovine F.S., et al. A genetic association between systemic lupus erythematosus and tumor necrosis factor-α. Eur. J. Immunol. 1994, 24:191-195.
240. Wilson A.G., Symons J.A., McDowell T.L., et al. Effects of a polymorphism in the human tumor necrosis factor-α promoter on transcriptional activation. Proc. Natl Acad. Sci. USA 1997, 94:3195-3199.
241. Winston B.W., Riches D.X. Activation of p42MAPK/ERK2 following engagement of tumor necrosis factor receptor CD120A (p55) in mouse macrophages. J. Immunol. 1995, 155:1525-1533.
242. Wong G.H., Goeddel D.V. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 1988, 242:941-944.
243. Xia Z., Dickens M., Raingeaud J., et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331.
244. Yokoyama T., Vaca L., Rossen R.D., et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J. Clin. Invest. 1993, 92:2303-2312.
245. Yoshimura T., Sone S. Different and synergistic actions of human tumor necrosis factor and interferon-γ in damage of liposome membranes. J. Biol. Chem. 1987, 262:4597-4601.
246. Young P., McDonnell P., Laydon J., et al. A novel MAP kinase regulates the production of IL-1 and TNF in LPS activated human monocytes. Cytokine 1994, 6:564.
247. Zhang M., Caragine T., Wang K., et al. Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells. J. Exp. Med. 1997, 185:1759-1768.
248. Zhang X.M., Weber I., Chen M.J. Site-directed mutational analysis of human tumor necrosis factor-α receptor binding site and structure-functional relationship. J. Biol. Chem. 1992, 267:24069-24075.
249. Zheng L., Fisher G., Miller R.E., et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995, 377:348-351.
250. Zhu W., Downey J.S., Gu J., et al. Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J. Immunol. 2000, 164:6349-6358.
251. Zimmerman R.J., Chan A., Leadon S.A. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res. 1989, 49:1644-1648.
252. Zubiaga A.M., Belasco J.G., Greenberg M.E. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol. Cell Biol. 1995, 15:2219-2230.
253. Zuniga J., Vargas-Alarcon G., Hernandez-Pacheco G., et al. tumor necrosis factor-alpha promoter polymorphisms in Mexican patients with systemic lupus erythematosus (SLE). Genes Immun. 2001, 2:363-366.